Arbutus Announces Conclusion of LNP License Agreement with Alexion
Arbutus Biopharma Corporation (ABUS)
Last arbutus biopharma corporation earnings: 11/6 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.arbutusbio.com/node/5806
Company Research
Source: GlobeNewswire
Alexion Decision Driven by Strategic Review of R&D Activities Collaboration Enabled Further Optimization of LNP for Delivery of mRNAArbutus Views LNP as a Potential Source of Significant Non-Dilutive Capital VANCOUVER, British Columbia and WARMINSTER, Pa., July 27, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has received notice of termination from Alexion Pharmaceuticals Holding (Alexion) for the companies’ LNP license agreement, which was signed and announced in March 2017. Alexion’s termination of the LNP license agreement was driven by a strategic review of Alexion’s business and research and development portfolio, which included a decision to discontinue development of mRNA therapeutics. “While we are disappointed to have our collaboration with Alexion come to an end, we are encouraged by the positive preclinical efficacy data generated and the advances
Show less
Read more
Impact Snapshot
Event Time:
ABUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABUS alerts
High impacting Arbutus Biopharma Corporation news events
Weekly update
A roundup of the hottest topics
ABUS
News
- Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments [Yahoo! Finance]Yahoo! Finance
- Arbutus to Participate in Two Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Arbutus to Participate in Two Upcoming Investor ConferencesGlobeNewswire
- Arbutus Biopharma Corporation (NASDAQ:ABUS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]Yahoo! Finance
- Analysts Just Made A Major Revision To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenue Forecasts [Yahoo! Finance]Yahoo! Finance
ABUS
Earnings
- 11/7/23 - In-Line
ABUS
Sec Filings
- 3/5/24 - Form 10-K
- 2/29/24 - Form 8-K
- 2/14/24 - Form SC
- ABUS's page on the SEC website